deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT00928187

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) (2LADY)

Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)

Sponsor: ANRS, Emerging Infectious Diseases

Conditions HIV HIV Infections
Interventions abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line) emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation) emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
Updated 8 times since 2017 Last updated: Jan 12, 2017 Started: Nov 30, 2009 Primary completion: Sep 30, 2013 Completion: Dec 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00928187, this PHASE3 trial focuses on HIV and HIV Infections and remains completed. Sponsored by ANRS, Emerging Infectious Diseases, it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotCompleted~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ANRS, Emerging Infectious Diseases
  • Gilead Sciences
  • Janssen Pharmaceutica
Data source: ANRS, Emerging Infectious Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations